Table 1.
Patient Demographics and Baseline Characteristics.
| Tacrolimus/Sirolimus N = 318 | Tacrolimus/MMF N = 316 | |
|---|---|---|
| Recipients | ||
| Age, mean (SD), y | 44.3 (11.3) | 44.9 (11.1) |
| Range, y | 18–66 | 18–72 |
| Male, Number (%) | 204 (64.2) | 204 (64.6) |
|
| ||
| Race, Number (%) | ||
| Caucasian | 299 (94.0) | 303 (95.9) |
| Black | 10 (3.1) | 7 (2.2) |
| Oriental | 7 (2.2) | 4 (1.3) |
| Other | 2 (0.6) | 2 (0.6) |
|
| ||
| Previous transplants, Number (%) | ||
| 0 | 306 (96.2) | 301 (95.3) |
| 1 | 12 (3.8) | 14 (4.4) |
| 3 | 0 (0.0) | 1 (0.3) |
| PRAa: 0%–50%, Number (%) | 316 (99.7) | 313 (100.0) |
| 50%–100%, Number (%) | 1 (0.3) | 0 (0.0) |
|
| ||
| Donors | ||
| Donation type: Number (%) | ||
| Living | 41 (12.9) | 32 (10.1) |
| Deceased | 277 (87.1) | 284 (89.9) |
|
| ||
| Transplant | ||
| ABO identical, Number (%) | 296 (93.1) | 295 (93.4) |
| Cold ischemia time, mean (SD), h | 16.1 (6.1) | 16.0 (5.8) |
| Mean total HLA mismatch | 2.9 | 3.0 |
| CMV status: Donor +/Recipient −, Number (%) | 47 (14.8) | 57 (18.0) |
FAS
aPRA not recorded for all patients.